Treatment of chronic hepatitis C in injecting drug users: 5 Years' follow-up

European Addiction Research

Volumn 8, Issue 1, 2002, Pages 45-49

  Dalgard, O ^a   Bjoro K ^b   Hellum, K ^c   Myrvang, B ^d   Skaug, K ^e   Gutigard, B ^e   Bell, H ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Follow up, long term; Hepatitis C; Interferon ; Reinfection; Substance abuse

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABUSE; DRUG DEPENDENCE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NORWAY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFECTION; TREATMENT OUTCOME; VIRUS TRANSMISSION;

EID: 18444397492     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049487     Document Type: Article

References (24)

1. Hepatitis C virus infection in Western Europe
2. Natural history of hepatitis C
3. A cost analysis of two strategies for evaluation and treatment of chronic HCV in the prison system: Treatment of all patients versus selective treatment based upon liver histology
4. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
5. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
6. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
7. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
8. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon
9. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
10. EASL International Consensus Conference on Hepatitis C. Paris, 26-27 February 1999. Consensus statement
11. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C
12. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a
13. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
14. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
15. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
16. Long-term course of interferon-treated chronic hepatitis C
17. Reinfection par le virus de l'hépatite C après une injection intraveineuse de drogue
18. Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease
19. Psychopathology, treatment completion and 5 years outcome. A prospective study of drug abusers
20. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence
21. Epidemiology of hepatitis C virus infection among injecting drug users in Australia
22. Lack of protective immunity against reinfection with hepatitis C virus
23. Prevalence and incidence of hepatitis C virus infection among young adult injection users